Benlysta in African Americans: FDA Explains Its Decision
This article was originally published in RPM Report
Executive Summary
FDA faced a tough challenge with Benlysta: how to label a lupus drug that failed to show a benefit in African Americans. Here is how FDA officials explained their decision to take a very hands-off approach.